Whitehawk Therapeutics, Inc. (WHWK)

From the record

Whitehawk Therapeutics, Inc.'s filings since 2017 show 5 warning events of 2 kinds: a notice about its exchange listing (8-K item 3.01, 3 times, the latest 2022-11-28); an auditor change (8-K item 4.01, 2 times, the latest 2021-09-13) (its current reports).

From the record

Whitehawk Therapeutics, Inc.'s 8 filed years say what it did: revenue went from $20 million in fiscal 2018 to $7 million in fiscal 2025, down 13.8% a year; it rose in 4 of 6 years; the deepest fall was 100% from fiscal 2018 to fiscal 2019; net income was positive in 0 of 8 of those years (its annual reports).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Whitehawk Therapeutics, Inc. lost about 15 cents for every dollar of shareholders' money, and gross profitability: its products earned about 4 cents per dollar of everything the company owns (revenue less the cost of revenue). Leverage: it owed about 10 cents per dollar of assets, and net share issuance: its share count grew 129.0% over the year (the filed statements).

From the record

Whitehawk Therapeutics, Inc.'s standing among 315 graded names in its industry family: revenue of $7 million in fiscal 2025 ranks in the bottom 37% by size; a net margin of -288.3% ranks in the bottom 43%; revenue growth of -22.3% a year over the last 3 filed years ranks in the bottom 20% (its annual reports).

From the record

Whitehawk Therapeutics, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Lennon, David James (CHIEF EXECUTIVE OFFICER, as filed), filing under that title since 2023-10-03, 3.1 years (bottom 34% of its family); most of the 14 officers and directors filing now have filed since the record of its people begins (2021-08-26), a floor of 4.3 years the record cannot see past, so that part is not read; 4 officer or director changes were reported on Form 8-K since 2023-11-13, against the 14 people in charge now (top 28%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Whitehawk Therapeutics, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $38 million against no long-term debt tagged leaves 24.9% of its assets as net cash, bottom 46% of its family; cash from operations less capital spending is -1371.4% of revenue (bottom 21%); a gross margin of 89.4% (top 16%); research spending of 1273.1% of revenue (top 18%) (its annual report).

From the record

Whitehawk Therapeutics, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew -22.3% a year over the last three filed years against -13.8% over all 8, slowing (bottom 38% of its family); the newest year grew -72.5% (bottom 8%); research spending grew 40.7% a year (top 11%); capital spending grew 7.5% a year (top 31%) (its annual reports). Whitehawk Therapeutics, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

From the record

Whitehawk Therapeutics, Inc.'s newest year against its own record: revenue of $7 million in fiscal 2025 came in 79% below the $34 million its prior three years' pace pointed to (bottom 10% of its family); net income of $21 million against a prior three-year average of $63 million (top 25%); a net margin of a loss larger than its revenue against losses larger than its revenue before (top 46%) (its annual reports).